Literature DB >> 22188568

Autoreactive-Aβ antibodies promote APP β-secretase processing.

Juan Deng1, Huayan Hou, Brian Giunta, Takashi Mori, Yan-Jiang Wang, Frank Fernandez, Sascha Weggen, Wataru Araki, Demian Obregon, Jun Tan.   

Abstract

Several prior investigations of Alzheimer's disease (AD) patients have indicated naturally occurring autoantibodies against amyloid-β (Aβ) species are produced. Although many studies have focused on the relative concentrations or binding affinities of autoantibodies against Aβ-related proteins in AD and aging, data regarding their functional properties are limited. It is generally believed that these antibodies act to aid in clearance of Aβ. However, as antibodies which bind to Aβ also typically bind to the parent amyloid precursor protein (APP), we reasoned that certain Aβ-targeting autoantibodies may bind to APP thereby altering its conformation and processing. Here we show for the first time, that naturally occurring Aβ-reactive autoantibodies isolated from AD patients, but not from healthy controls, promote β-secretase activity in cultured cells. Furthermore, using monoclonal antibodies to various regions of Aβ, we found that antibodies generated against the N-terminal region, especially Aβ(1-17) , dose dependently promoted amyloidogenic processing of APP viaβ-secretase activation. Thus, this property of certain autoantibodies in driving Aβ generation could be of etiological importance in the development of sporadic forms of AD. Furthermore, future passive or active anti-Aβ immunotherapies must consider potential off-target effects resulting from antibodies targeting the N-terminus of Aβ, as co-binding to the corresponding region of APP may actually enhance Aβ generation.
© 2011 The Authors. Journal of Neurochemistry © 2011 International Society for Neurochemistry.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22188568      PMCID: PMC3278497          DOI: 10.1111/j.1471-4159.2011.07629.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  34 in total

1.  Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.

Authors:  Dominic M Walsh; Igor Klyubin; Julia V Fadeeva; William K Cullen; Roger Anwyl; Michael S Wolfe; Michael J Rowan; Dennis J Selkoe
Journal:  Nature       Date:  2002-04-04       Impact factor: 49.962

2.  Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain.

Authors:  Sascha Weggen; Jason L Eriksen; Sarah A Sagi; Claus U Pietrzik; Todd E Golde; Edward H Koo
Journal:  J Biol Chem       Date:  2003-05-31       Impact factor: 5.157

3.  Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization.

Authors:  J-M Orgogozo; S Gilman; J-F Dartigues; B Laurent; M Puel; L C Kirby; P Jouanny; B Dubois; L Eisner; S Flitman; B F Michel; M Boada; A Frank; C Hock
Journal:  Neurology       Date:  2003-07-08       Impact factor: 9.910

4.  Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease.

Authors:  R B DeMattos; K R Bales; D J Cummins; J C Dodart; S M Paul; D M Holtzman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

5.  Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice.

Authors:  Jun Tan; Terrence Town; Fiona Crawford; Takashi Mori; Anthony DelleDonne; Robert Crescentini; Demian Obregon; Richard A Flavell; Michael J Mullan
Journal:  Nat Neurosci       Date:  2002-12       Impact factor: 24.884

6.  Reduced levels of amyloid beta-peptide antibody in Alzheimer disease.

Authors:  Y Du; R Dodel; H Hampel; K Buerger; S Lin; B Eastwood; K Bales; F Gao; H J Moeller; W Oertel; M Farlow; S Paul
Journal:  Neurology       Date:  2001-09-11       Impact factor: 9.910

7.  A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.

Authors:  D Morgan; D M Diamond; P E Gottschall; K E Ugen; C Dickey; J Hardy; K Duff; P Jantzen; G DiCarlo; D Wilcock; K Connor; J Hatcher; C Hope; M Gordon; G W Arendash
Journal:  Nature       Date:  2000 Dec 21-28       Impact factor: 49.962

8.  Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease.

Authors:  Alon Monsonego; Victor Zota; Arnon Karni; Jeffery I Krieger; Amit Bar-Or; Gal Bitan; Andrew E Budson; Reisa Sperling; Dennis J Selkoe; Howard L Weiner
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

9.  Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals.

Authors:  Marc E Weksler; Norman Relkin; Rimma Turkenich; Susan LaRusse; Ling Zhou; Paul Szabo
Journal:  Exp Gerontol       Date:  2002-07       Impact factor: 4.032

10.  Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction.

Authors:  Jennifer L Tomic; Anna Pensalfini; Elizabeth Head; Charles G Glabe
Journal:  Neurobiol Dis       Date:  2009-06-10       Impact factor: 5.996

View more
  10 in total

Review 1.  Immunotherapy for Alzheimer disease: the challenge of adverse effects.

Authors:  Yu-Hui Liu; Brian Giunta; Hua-Dong Zhou; Jun Tan; Yan-Jiang Wang
Journal:  Nat Rev Neurol       Date:  2012-07-03       Impact factor: 42.937

2.  Naturally-Occurring Antibodies Against Bim are Decreased in Alzheimer's Disease and Attenuate AD-type Pathology in a Mouse Model.

Authors:  Jie-Ming Jian; Dong-Yu Fan; Ding-Yuan Tian; Yuan Cheng; Pu-Yang Sun; Cheng-Rong Tan; Gui-Hua Zeng; Chen-Yang He; Ye-Ran Wang; Jie Zhu; Xiu-Qing Yao; Yan-Jiang Wang; Yu-Hui Liu
Journal:  Neurosci Bull       Date:  2022-05-15       Impact factor: 5.271

3.  Mycoplasma hyorhinis markedly degrades β-amyloid peptides in vitro and ex vivo: a novel biological approach for treating Alzheimer's disease?

Authors:  Ahsan Habib; Juan Deng; Huayan Hou; Qiang Zou; Brian Giunta; Yan-Jiang Wang; Demian Obregon; Darrell Sawmiller; Song Li; Takashi Mori; Jun Tan
Journal:  Am J Transl Res       Date:  2013-09-25       Impact factor: 4.060

Review 4.  Clearance of amyloid-beta in Alzheimer's disease: shifting the action site from center to periphery.

Authors:  Yu-Hui Liu; Ye-Ran Wang; Yang Xiang; Hua-Dong Zhou; Brian Giunta; Noralyn B Mañucat-Tan; Jun Tan; Xin-Fu Zhou; Yan-Jiang Wang
Journal:  Mol Neurobiol       Date:  2014-04-15       Impact factor: 5.590

5.  An N-terminal antibody promotes the transformation of amyloid fibrils into oligomers and enhances the neurotoxicity of amyloid-beta: the dust-raising effect.

Authors:  Yu-Hui Liu; Xian-Le Bu; Chun-Rong Liang; Ye-Ran Wang; Tao Zhang; Shu-Sheng Jiao; Fan Zeng; Xiu-Qing Yao; Hua-Dong Zhou; Juan Deng; Yan-Jiang Wang
Journal:  J Neuroinflammation       Date:  2015-08-28       Impact factor: 8.322

6.  Specific antibody binding to the APP672-699 region shifts APP processing from α- to β-cleavage.

Authors:  S Li; J Deng; H Hou; J Tian; B Giunta; Y Wang; D Sawmiller; A Smith; P R Sanberg; D Obregon; T Mori; J Tan
Journal:  Cell Death Dis       Date:  2014-08-14       Impact factor: 8.469

Review 7.  Open questions for Alzheimer's disease immunotherapy.

Authors:  Todd E Golde
Journal:  Alzheimers Res Ther       Date:  2014-01-07       Impact factor: 6.982

8.  SIRT3 activator Honokiol attenuates β-Amyloid by modulating amyloidogenic pathway.

Authors:  Sindhu Ramesh; Manoj Govindarajulu; Tyler Lynd; Gwyneth Briggs; Danielle Adamek; Ellery Jones; Jake Heiner; Mohammed Majrashi; Timothy Moore; Rajesh Amin; Vishnu Suppiramaniam; Muralikrishnan Dhanasekaran
Journal:  PLoS One       Date:  2018-01-11       Impact factor: 3.240

9.  Association of naturally occurring antibodies to β-amyloid with cognitive decline and cerebral amyloidosis in Alzheimer's disease.

Authors:  Yu-Hui Liu; Jun Wang; Qiao-Xin Li; Christopher J Fowler; Fan Zeng; Juan Deng; Zhi-Qiang Xu; Hua-Dong Zhou; James D Doecke; Victor L Villemagne; Yen Ying Lim; Colin L Masters; Yan-Jiang Wang
Journal:  Sci Adv       Date:  2021-01-01       Impact factor: 14.136

10.  Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer's disease.

Authors:  Yang Xiang; Xian-Le Bu; Yu-Hui Liu; Chi Zhu; Lin-Lin Shen; Shu-Sheng Jiao; Xiao-Yan Zhu; Brian Giunta; Jun Tan; Wei-Hong Song; Hua-Dong Zhou; Xin-Fu Zhou; Yan-Jiang Wang
Journal:  Acta Neuropathol       Date:  2015-09-12       Impact factor: 17.088

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.